Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
about
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.Peripartum cardiomyopathy, what if your patient plans to reconceive?Reducing the risks for relapse of heart failure in a subsequent pregnancy after peripartum cardiomyopathy?The Role of Cardiac Biomarkers in Pregnancy.Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population.Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy.
P2860
Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Relaxin-2 and Soluble Flt1 Lev ...... of the Multicenter IPAC Study.
@en
type
label
Relaxin-2 and Soluble Flt1 Lev ...... of the Multicenter IPAC Study.
@en
prefLabel
Relaxin-2 and Soluble Flt1 Lev ...... of the Multicenter IPAC Study.
@en
P2093
P2860
P1433
P1476
Relaxin-2 and Soluble Flt1 Lev ...... of the Multicenter IPAC Study.
@en
P2093
Biykem Bozkurt
Dennis M McNamara
Gregory Ewald
Hal Skopicki
IPAC Investigators
Indrani Halder
James D Fett
Jennifer Haythe
Jessica Pisarcik
John Boehmer
P2860
P304
P356
10.1016/J.JCHF.2016.01.004
P50
P577
2016-02-27T00:00:00Z